Aspira Women’s Health (NASDAQ:AWH) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.

Separately, Cantor Fitzgerald reaffirmed a neutral rating and issued a $3.30 price target on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.

Aspira Women’s Health Price Performance

Shares of AWH opened at $1.49 on Wednesday. Aspira Women’s Health has a 1-year low of $1.14 and a 1-year high of $6.75. The firm’s 50 day simple moving average is $2.44 and its 200 day simple moving average is $3.42. The company has a market capitalization of $18.55 million, a P/E ratio of -1.03 and a beta of 1.50.

Aspira Women’s Health (NASDAQ:AWH) last issued its quarterly earnings results on Tuesday, May 21st. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Aspira Women’s Health had a negative net margin of 163.95% and a negative return on equity of 1,099.32%. The business had revenue of $2.15 million for the quarter, compared to the consensus estimate of $2.10 million. During the same quarter in the previous year, the business earned ($10.94) earnings per share. On average, equities analysts anticipate that Aspira Women’s Health will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. raised its position in shares of Aspira Women’s Health by 43.1% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 179,371 shares of the company’s stock worth $732,000 after purchasing an additional 53,997 shares during the last quarter. Quantum Private Wealth LLC raised its position in shares of Aspira Women’s Health by 76.8% in the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after purchasing an additional 21,788 shares during the last quarter. Finally, Northeast Financial Consultants Inc bought a new stake in Aspira Women’s Health in the 3rd quarter worth about $126,000. Hedge funds and other institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.